Drug Type Small molecule drug |
Synonyms- |
Target |
Action inhibitors, stimulants |
Mechanism E2F1 inhibitors(Transcription factor E2F1 inhibitors), MUC4 inhibitors(mucin 4, cell surface associated inhibitors), PTEN stimulators(Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC10H12O2 |
InChIKeyKEQHJBNSCLWCAE-UHFFFAOYSA-N |
CAS Registry490-91-5 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Gingivitis | Phase 1 | Saudi Arabia | 01 Sep 2022 | |
| Hepatitis C | Preclinical | Egypt | 03 May 2025 | |
| Alzheimer Disease | Preclinical | Turkey | 07 Apr 2025 | |
| Hormone receptor positive breast cancer | Preclinical | Egypt | 16 Sep 2021 | |
| Hormone receptor positive breast cancer | Preclinical | - | 16 Sep 2021 | |
| Non-Small Cell Lung Cancer | Preclinical | United States | 01 Jul 2018 | |
| Kidney Neoplasms | Preclinical | South Korea | 15 Jul 2016 | |
| Triple Negative Breast Cancer | Preclinical | United States | 15 Jul 2016 | |
| Diffuse Large B-Cell Lymphoma | Preclinical | Saudi Arabia | 15 Apr 2012 | |
| Primary Effusion Lymphoma | Preclinical | United States | 01 May 2009 |





